Table 4.
Coverage of PMTCT services among adolescent and adult mothers whose infants were EIAa positive in the 2010, 2011–2012, and 2012–2013 PMTCT surveys, South Africa
| Characteristics | Categories | 2010 | 2011–2012 | 2012–2013 | |||
|---|---|---|---|---|---|---|---|
|
|
|
|
|||||
| Adolescentsb | Adultsc | Adolescentsb | Adultsc | Adolescentsb | Adultsc | ||
| Sample size | Actual | 198 | 2,909 | 199 | 2,818 | 140 | 2,737 |
| Weighted | 26,286 | 386,348 | 25,976 | 356,871 | 19,138 | 360,665 | |
| Aware of CD4 cell count (%) | Yes | 66.1 (56.8–74.4) | 75.3 (73.4–77.2) | 73.1 (64.8–80.0) | 78.0 (76.2–79.7) | 44.6 (35.0–54.7) | 66.5 (64.6–68.4) |
| p Value | .047 | .2206 | <.0001 | ||||
| On any antenatal PMTCT interventiond (%) | Yes | 58.1 (50.3–65.5) | 77.0 (75.4–78.7) | 67.9 (60.3–74.6) | 76.5 (74.7–78.1) | 81.4 (73.6–87.3) | 89.3 (81.1–90.5) |
| p Value | <.0001 | .02 | .025 | ||||
| Timing of the initiation of ART among those on ART (%) | Before pregnancy | 24.7 (10.6–49.2) | 37.2 (33.6–40.9) | 15.5 (6.3–33.1) | 36.0 (32.8–39.3) | 27.6 (16.1–42.9) | 42.7 (40.0–45.3) |
| p Value | .22 | .0027 | .036 | ||||
| During pregnancy | 59.4 (36.4–78.9) | 56.7 (52.0–60.3) | 70.2 (51.9–83.7) | 59.5 (56.2–62.7) | 69.3 (53.9–81.5) | 55.3 (52.6–58.0) | |
| p Value | .81 | .21 | .054 | ||||
| After pregnancy | 15.9 (5.2–39.5) | 6.1 (4.5–8.2) | 14.3 (5.9–30.7) | 4.4 (3.2–6.0) | 3.0 (.6–12.2) | 1.9 (1.3–2.8) | |
| p Value | .25 | .11 | .62 | ||||
a
ART = antiretroviral treatment; EIA = enzyme immunoassay; PMTCT = prevention of mother-to-child transmission.
b
Adolescents defined as mothers ≤19 years.
c
Adults defined as mothers ≥20 years.
d
PMTCT intervention defined as mothers who received triple ART or antenatal azidothymidine or antiretroviral medication during labor or infant nevirapine.